Brokerages forecast that Integra Lifesciences Holdings Corp (NASDAQ:IART) will announce $370.61 million in sales for the current quarter, according to Zacks. Six analysts have issued estimates for Integra Lifesciences’ earnings. The lowest sales estimate is $368.80 million and the highest is $373.10 million. Integra Lifesciences posted sales of $278.83 million during the same quarter last year, which suggests a positive year-over-year growth rate of 32.9%. The company is scheduled to report its next quarterly earnings report before the market opens on Thursday, October 25th.

On average, analysts expect that Integra Lifesciences will report full year sales of $1.49 billion for the current year, with estimates ranging from $1.48 billion to $1.49 billion. For the next year, analysts forecast that the business will report sales of $1.57 billion, with estimates ranging from $1.56 billion to $1.60 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that follow Integra Lifesciences.

Integra Lifesciences (NASDAQ:IART) last posted its quarterly earnings data on Wednesday, July 25th. The life sciences company reported $0.60 EPS for the quarter, hitting the consensus estimate of $0.60. The firm had revenue of $366.20 million during the quarter, compared to analyst estimates of $368.08 million. Integra Lifesciences had a net margin of 5.10% and a return on equity of 17.43%. Integra Lifesciences’s revenue was up 29.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.45 EPS.

Several research analysts recently commented on IART shares. Zacks Investment Research lowered shares of Integra Lifesciences from a “buy” rating to a “hold” rating in a research note on Tuesday, June 26th. Citigroup lowered shares of Integra Lifesciences from a “buy” rating to a “neutral” rating and boosted their price objective for the stock from $64.00 to $66.00 in a research note on Monday, July 2nd. BidaskClub lowered shares of Integra Lifesciences from a “strong-buy” rating to a “buy” rating in a research note on Thursday, July 12th. Oppenheimer reiterated a “buy” rating and set a $74.00 price objective on shares of Integra Lifesciences in a research note on Wednesday, July 25th. Finally, Cantor Fitzgerald reiterated a “hold” rating and set a $59.00 price objective on shares of Integra Lifesciences in a research note on Wednesday, July 25th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $62.15.

Shares of NASDAQ IART traded up $1.30 during trading hours on Friday, hitting $61.96. 765,533 shares of the stock were exchanged, compared to its average volume of 723,541. The company has a quick ratio of 2.27, a current ratio of 3.52 and a debt-to-equity ratio of 1.10. The firm has a market cap of $5.61 billion, a PE ratio of 31.94, a price-to-earnings-growth ratio of 2.03 and a beta of 0.57. Integra Lifesciences has a 12 month low of $41.51 and a 12 month high of $67.50.

In other Integra Lifesciences news, insider Jeffrey Mosebrook sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, August 10th. The shares were sold at an average price of $62.42, for a total transaction of $62,420.00. Following the transaction, the insider now owns 3,085 shares in the company, valued at approximately $192,565.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Stuart Essig sold 31,353 shares of the company’s stock in a transaction that occurred on Tuesday, July 17th. The shares were sold at an average price of $63.50, for a total transaction of $1,990,915.50. Following the transaction, the director now owns 1,450,272 shares in the company, valued at approximately $92,092,272. The disclosure for this sale can be found here. Insiders have sold a total of 111,140 shares of company stock worth $7,054,647 in the last 90 days. 5.10% of the stock is currently owned by company insiders.

A number of institutional investors have recently modified their holdings of IART. FMR LLC increased its stake in Integra Lifesciences by 11.8% during the 2nd quarter. FMR LLC now owns 11,078,120 shares of the life sciences company’s stock valued at $713,542,000 after purchasing an additional 1,166,483 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Integra Lifesciences in the 2nd quarter valued at $46,263,000. Westwood Holdings Group Inc. purchased a new stake in shares of Integra Lifesciences in the 1st quarter valued at $32,180,000. Janus Henderson Group PLC boosted its holdings in shares of Integra Lifesciences by 22.8% in the 2nd quarter. Janus Henderson Group PLC now owns 1,966,341 shares of the life sciences company’s stock valued at $126,652,000 after acquiring an additional 365,254 shares during the last quarter. Finally, Castleark Management LLC purchased a new stake in shares of Integra Lifesciences in the 2nd quarter valued at $18,130,000. Institutional investors and hedge funds own 84.41% of the company’s stock.

Integra Lifesciences Company Profile

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Featured Article: What are the Different Types of Leveraged Buyouts?

Get a free copy of the Zacks research report on Integra Lifesciences (IART)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.